Page last updated: 2024-08-24

topotecan and Thrombocytopenia

topotecan has been researched along with Thrombocytopenia in 62 studies

Research

Studies (62)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	20 (32.26)	18.2507
2000's	33 (53.23)	29.6817
2010's	9 (14.52)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Belani, C; Cristea, MC; Gandara, DR; Gitlitz, BJ; Goldkorn, A; Gong, IY; Groshen, SG; Kelly, K; Koczywas, M; Liu, SV; Newman, EM; Reckamp, KL; Semrad, TJ; Synold, TW; Xu, T; Xu, Y	1
Agelaki, S; Bompolaki, I; Chandrinos, V; Georgoulias, V; Kalbakis, K; Kontopodis, E; Kotsakis, A; Papadimitraki, E; Stoltidis, D; Zafeiriou, Z	1
Bender, DP; Carter, JS; Dawson, D; Deng, W; Gray, HJ; Guaglianone, PP; Kunos, C; Lea, JS; Moore, KN; Zanotti, KM	1
Chao, Z; Chen, XM; Deng, CX; DU, X; Huang, X; Lai, PL; Li, MM; Liao, PJ; Ling, W; Lu, ZS; Wan, CC; Wang, YL; Weng, JY; Wu, SJ; Zhong, LY; Zou, XL	1
Borad, MJ; Curtis, KK; Fitch, TR; Griffin, PP; Hartney, JT; Jewell, RC; Lebowitz, PF; Northfelt, DW; Park, JW	1
Anagnostopoulos, A; Antoniou, D; Ardavanis, A; Athanasiadis, A; Koutantos, J; Papadopoulos, G; Papakotoulas, P; Pectasides, D; Stathopoulos, GP; Trafalis, D; Vaslamatzis, M	1
Conkling, P; Fitzgibbons, JF; Galsky, MD; Jotte, R; Klein, L; McNally, R; Oliver, JW; Renschler, MF; Reynolds, C	1
Brown, A; Ginsberg, MS; James, L; Juergens, R; Kris, MG; Krug, LM; Markus, S; Paik, PK; Pietanza, MC; Rizvi, NA; Rudin, CM; Subzwari, S; Takebe, N; Travis, W; Tyson, L	1
Billups, CA; Brennan, R; Free, TM; Given, V; Haik, BG; Helton, K; McCarville, MB; Merchant, TE; Qaddoumi, I; Rodriguez-Galindo, C; Stewart, CF; Tagen, M; Wilson, MW; Wu, J	1
Goldwasser, F; Gross-Goupil, M; Hasbini, A; Lokiec, F; Lopez, G; Misset, JL; Romain, D; Tigaud, JM	1
Agelidou, M; Ferdoutsis, E; Georgoulias, V; Kalbakis, K; Kouroussis, Ch; Magkanas, E; Mavroudis, D; Samonis, G; Souglakos, J; Toumbis, M; Tselepatiotis, E; Tzanakis, N; Veslemes, M; Ziotopoulos, P	1
Biggs, DD; Grubbs, SS; Guarino, MJ; Himelstein, AL; Hogaboom, K; Schneider, CJ; Tilak, S	1
Anders, K; Feldmann, HJ; Fietkau, RJ; Grabenbauer, GG; Klautke, G; Krauseneck, P; Sauer, R; Staab, HJ; Weiser, S	1
Blohmer, J; Kaubitzsch, S; Lichtenegger, W; Oskay, G; Sehouli, J; Stengel, D	1
Baselga, J; Carrato, A; Domine, M; Felip, E; Font, A; Garrido, P; Mañe, JM; Rosell, R; Santomé, L; Terrasa, J; Vadell, C	1
Belani, CP; Day, R; Jacobs, SA; Jett, JR; Ramalingam, S; Zamboni, BA	1
Berlin, J; Boothman, D; Forouzannia, A; Hutson, P; Mehta, M; Schiller, J; Storer, B; Wilding, G	1
Ambaum, B; Beijnen, JH; Groenewegen, G; Herben, VM; Jansen, S; Kerbusch, T; Mathôt, RA; Rosing, H; Schellens, JH; Swart, M; ten Bokkel Huinink, WW; Voest, EE	1
Biamonte, R; Cartenì, G; Danese, S; De Laurentiis, M; De Matteis, A; De Placido, S; Di Vagno, G; Febbraro, A; Gallo, C; Gasparini, G; Greggi, S; Lauria, R; Lombardi, AV; Manzione, L; Marinaccio, M; Naglieri, E; Perrone, F; Pignata, S; Scambia, G; Valerio, MR	1
Cromwell, LD; Fadul, CE; Kingman, LS; McDonnell, CE; Meyer, LP; Pipas, JM; Rhodes, CH; Rigas, JR	1
Buchholz, E; Gatzemeier, U; Goetz, E; Groth, G; Manegold, C; Reck, M	1
Brunetti, C; Cassano, G; Colucci, G; Galetta, D; Gebbia, V; Germano, D; Giampaglia, M; Guida, M; Izzi, G; Lorusso, V; Nettis, G; Silvestris, N; Spada, M	1
Adamson, PC; Blaney, SM; Bradfield, S; Franklin, J; Hawkins, DS; Krailo, M; Reaman, G; Whitlock, JA	1
Alberti, D; Arzoomanian, R; Binger, K; Dubey, S; Feierabend, C; Hutson, P; Schiller, JH; Volkman, J; Wilding, G	1
Armand, JP; Djafari, L; Djazouli, K; Faivre, S; Ghesquières, H; Lhommé, C; Lozahic, S; Pautier, P; Raymond, E	1
Aravantinos, G; Christodoulou, Ch; Malamos, NA; Rigatos, S; Skarlos, D; Stathopoulos, GP; Stathopoulos, J	1
Aydiner, A; Camlica, H; Derin, D; Guney, N; Tas, F; Topuz, E	1
Gajra, A; Garziano, S; Kirshner, J; Neuman, N; Perry, M; Ready, N; Shah, C	1
Barr, P; Cooper, B; Creger, R; Fu, P; Hartman, P; Kane, D; Laughlin, M; Lazarus, H; Meyerson, H; Reyes, R; Stear, K; Tse, W	1
Brewster, L; Green, MR; Hargis, JB; Hollis, DR; Lilenbaum, RC; Miller, AA; O'Brien, SM; Ratain, MJ; Rosner, GL; Schilsky, RL	1
Beijnen, JH; Davies, BE; Koier, I; Maes, RA; Rodenhuis, S; Rosing, H; ten Bokkel Huinink, WW; van Warmerdam, LJ	1
Fossella, FV; Glisson, BS; Hong, WK; Huber, MH; Kane, J; Kemp, BL; Kurie, JM; Lee, JJ; Lee, JS; Lippman, SM; Murphy, WK; Perez-Soler, R; Raber, MN; Robinson, RA; Shin, DM	1
Beijnen, JH; Creemers, GJ; Davies, BE; de Boer-Dennert, M; Maes, RA; Rodenhuis, S; Rosing, H; Schellens, JH; ten Bokkel Huinink, WW; van Warmerdam, LJ; Verweij, J	1
Fossella, FV; Glisson, BS; Hong, WK; Lee, JS; Murphy, WK; Perez-Soler, R; Shin, DM	1
Alvarez, RD; Armstrong, DK; Barker, SD; Bookman, MA; Fleming, GF; Horowitz, IR; McGuire, WP; O'Reilly, S; Ozols, RF; Rowinsky, EK; Schilder, RJ; Walczak, JR	1
Broom, C; Burris, HA; Creemers, GJ; Eckardt, JR; Gerrits, CJ; Hudson, I; Loos, WJ; Planting, AS; Rodriguez, GI; Schellens, JH; Verweij, J; Von Hoff, DD	1
Benedetti, JK; Macdonald, JS; Natale, RB; O'Rourke, MA; Wall, JG	1
Burris, HA; Eckardt, JR; Raymond, E; Rodriguez, G; Rowinsky, EK; Smith, L; Von Hoff, DD; Weiss, G	1
Cass, I; Fields, AL; Goldberg, GL; Kuo, DY; Runowicz, CD	1
Abendstein, B; Klingler, PJ; Sevin, BU	1
Beijnen, JH; Herben, VM; Hudson, I; Schot, ME; ten Bokkel Huinink, WW	1
Batist, G; Bernard, S; Egorin, MJ; Hollis, DR; Lilenbaum, RC; Miller, AA; Ratain, MJ; Rosner, GL; Schilsky, RL	1
Bolis, G; Bookman, MA; Fields, SZ; Gordon, A; Krebs, JB; Lissoni, A; Malmström, H	1
Blum, RH; Chachoua, A; Hochster, H; Liebes, L; Oratz, R; Sorich, J; Speyer, J; Taubes, B; Wernz, J; Zeleniuch-Jacquotte, A	1
Abbruzzese, JL; Ellis, AL; Hess, KR; Loughlin, S; Madden, T; Newman, RA; Raber, MN; Sugarman, SM; Zwelling, LA	1
Beijnen, JH; Beusenberg, FD; Doyle, E; Hearn, S; Herben, VM; Panday, VR; Richel, DJ; Rosing, H; Schellens, JH; ten Bokkel Huinink, WW; van der Vange, N	1
Burris, HA; Greco, FA; Hainsworth, JD; Morrissey, LH	1
Bleuzen, P; Buthaud, X; Cvitkovic, E; Goldwasser, F; Gross, M; Jasmin, C; Misset, JL; Romain, D; Voinea, A	1
Beran, M; Kantarjian, H	1
Bate, WW; Grill, JP; Hatfield, AK; Jett, JR; Knost, JA; Marschke, RF; Schaefer, PL; Sloan, JA; Weitz, JJ; Zenk, DW	1
Cacciari, N; Martoni, A; Zamagni, C	1
Alvarez, RD; Blessing, JA; Hall, K; Hanjani, P; Markman, M; Waggoner, S	1
Anderson, H; Carrington, B; Cheeseman, S; Hearn, S; Ranson, M; Ross, G; Thatcher, N; White, SC	1
Brouwer, E; de Jonge, MJ; Doyle, E; Gelderblom, H; Hearn, S; Loos, WJ; Mantel, MA; Planting, AS; Ross, G; Sparreboom, A; van Beurden, V; van der Burg, ME; Verweij, J	1
Fleming, GF; Janisch, L; Ratain, MJ; Ryan, CW	1
Blessing, JA; Kilgore, LC; Mannel, R; Miller, DS; Van Le, L	1
Hansen, HH; Herrstedt, J; Hirsch, FR; Jensen, PB; Sorensen, M	1
Conlon, KC; Curti, BD; Gause, BL; Janik, JE; Korn, EL; Longo, DL; Miller, LL; Sharfman, W; Smith, JW; Stevens, D; Sznol, M; Urba, WJ	1
Brunetti, C; Carreca, I; Comella, G; Comella, P; DeCataldis, G; Frasci, G; Muci, D; Natale, M; Nicolella, G; Palmeri, S; Panza, N; Piantedosi, F; Russo, A	1
Barnes, B; Brierre, J; Buller, E; Cole, J; Fontenot, F; Lormand, N; Rainey, J; Rinaldi, D	1
Algazy, K; Gallagher, M; Giantonio, B; Haller, D; O'Dwyer, PJ; Raskay, BJ; Stevenson, JP; Sun, W; Vaughn, D	1
Agelaki, S; Androulakis, N; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kouroussis, C; Mavroudis, D; Souglakos, J; Vamvakas, L; Vardakis, N	1

Trials

56 trial(s) available for topotecan and Thrombocytopenia

Article	Year
A phase I trial of topotecan plus tivantinib in patients with advanced solid tumors. Cancer chemotherapy and pharmacology, 2018, Volume: 82, Issue:4 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Monitoring; Female; Humans; Male; Middle Aged; Neoplasm Staging; Neoplasms; Neutropenia; Proto-Oncogene Proteins c-met; Pyrrolidinones; Quinolines; Thrombocytopenia; Topotecan; Treatment Failure; Treatment Outcome	2018
A phase I clinical trial of weekly oral topotecan for relapsed small cell lung cancer. Cancer chemotherapy and pharmacology, 2013, Volume: 72, Issue:1 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anemia; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Monitoring; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Palliative Care; Small Cell Lung Carcinoma; Thrombocytopenia; Topoisomerase I Inhibitors; Topotecan	2013
A phase I-II evaluation of veliparib (NSC #737664), topotecan, and filgrastim or pegfilgrastim in the treatment of persistent or recurrent carcinoma of the uterine cervix: an NRG Oncology/Gynecologic Oncology Group study. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2015, Volume: 25, Issue:3 Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carcinoma; Cell Cycle Proteins; Disease Progression; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Polyethylene Glycols; Recombinant Proteins; Ribonucleotide Reductases; Thrombocytopenia; Topotecan; Uterine Cervical Neoplasms	2015
A phase I study to characterize the safety, tolerability, and pharmacokinetics of topotecan at 4 mg/m2 administered weekly as a 30-minute intravenous infusion in patients with cancer. Journal of clinical pharmacology, 2010, Volume: 50, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Biological Availability; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Tolerance; Fatigue; Female; Humans; Infusions, Intravenous; Leukopenia; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Thrombocytopenia; Topotecan	2010
Myelotoxicity of oral topotecan in relation to treatment duration and dosage: a phase I study. Anti-cancer drugs, 2010, Volume: 21, Issue:2 Topics: Administration, Oral; Aged; Antineoplastic Agents; Cohort Studies; Dose-Response Relationship, Drug; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Prognosis; Small Cell Lung Carcinoma; Survival Rate; Thrombocytopenia; Time Factors; Topotecan; Treatment Outcome	2010
Randomized phase II trial of single-agent amrubicin or topotecan as second-line treatment in patients with small-cell lung cancer sensitive to first-line platinum-based chemotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Jan-20, Volume: 29, Issue:3 Topics: Adolescent; Adult; Aged; Anthracyclines; Antineoplastic Agents; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Intention to Treat Analysis; Lung Neoplasms; Male; Middle Aged; Neutropenia; Small Cell Lung Carcinoma; Survival Analysis; Thrombocytopenia; Topoisomerase I Inhibitors; Topotecan; United States	2011
A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer. Lung cancer (Amsterdam, Netherlands), 2011, Volume: 74, Issue:3 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Disease Progression; Female; Humans; Indoles; Lung Neoplasms; Middle Aged; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Recurrence; Thrombocytopenia; Topotecan	2011
Topotecan and vincristine combination is effective against advanced bilateral intraocular retinoblastoma and has manageable toxicity. Cancer, 2012, Nov-15, Volume: 118, Issue:22 Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Female; Granulocyte Colony-Stimulating Factor; Humans; Infant; Male; Neutropenia; Retinal Neoplasms; Retinoblastoma; Survival Rate; Thrombocytopenia; Topoisomerase I Inhibitors; Topotecan; Vincristine	2012
Topotecan preceded by oxaliplatin using a 3 week schedule: a phase I study in advanced cancer patients. European journal of cancer (Oxford, England : 1990), 2002, Volume: 38, Issue:14 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Drug Synergism; Female; Fever; Humans; Infections; Male; Middle Aged; Neoplasms; Nervous System Diseases; Neutropenia; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Patient Dropouts; Thrombocytopenia; Topotecan; Treatment Outcome	2002
Cisplatin-etoposide alternating with topotecan in patients with extensive stage small cell lung cancer (SCLC). A multicenter phase II study. Lung cancer (Amsterdam, Netherlands), 2002, Volume: 38, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Disease Progression; Drug Administration Schedule; Etoposide; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Survival; Thrombocytopenia; Topotecan; Treatment Outcome	2002
A dose-escalation study of weekly topotecan, cisplatin, and gemcitabine front-line therapy in patients with inoperable non-small cell lung cancer. The oncologist, 2002, Volume: 7, Issue:6 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Survival Analysis; Thrombocytopenia; Topotecan; Treatment Outcome	2002
Prolonged infusional topotecan and accelerated hyperfractionated 3d-conformal radiation in patients with newly diagnosed glioblastoma--a phase I study. Journal of neuro-oncology, 2002, Volume: 60, Issue:3 Topics: Adult; Aged; Antineoplastic Agents; Central Nervous System Neoplasms; Combined Modality Therapy; Glioblastoma; Humans; Infusions, Intravenous; Maximum Tolerated Dose; Middle Aged; Neutropenia; Radiotherapy, Conformal; Sepsis; Sinusitis; Thrombocytopenia; Topotecan	2002
Sequential dose-dense paclitaxel followed by topotecan in untreated extensive-stage small-cell lung cancer: a Spanish Lung Cancer Group phase II study. Annals of oncology : official journal of the European Society for Medical Oncology, 2003, Volume: 14, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Survival Analysis; Thrombocytopenia; Topotecan	2003
Phase II study of topotecan and paclitaxel for patients with previously untreated extensive stage small-cell lung cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2004, Volume: 15, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Survival Analysis; Thrombocytopenia; Topotecan	2004
A phase I study of Topotecan, as a radiosensitizer, for thoracic malignancies. Lung cancer (Amsterdam, Netherlands), 2004, Volume: 44, Issue:1 Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Diarrhea; Esophagitis; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Radiation-Sensitizing Agents; Thoracic Neoplasms; Thrombocytopenia; Topotecan; Treatment Outcome	2004
Phase I and pharmacokinetic study of the combination of topotecan and ifosfamide administered intravenously every 3 weeks. British journal of cancer, 2004, Jun-14, Volume: 90, Issue:12 Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Interactions; Female; Humans; Ifosfamide; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neutropenia; Thrombocytopenia; Topotecan	2004
Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jul-01, Volume: 22, Issue:13 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Disease-Free Survival; Female; Humans; Infusions, Intravenous; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Thrombocytopenia; Topotecan; Treatment Outcome	2004
A Phase II trial of paclitaxel and topotecan with filgrastim in patients with recurrent or refractory glioblastoma multiforme or anaplastic astrocytoma. Journal of neuro-oncology, 2005, Volume: 71, Issue:3 Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Filgrastim; Glioblastoma; Granulocyte Colony-Stimulating Factor; Humans; Leukopenia; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Recombinant Proteins; Thrombocytopenia; Topotecan; Treatment Outcome	2005
Topotecan and etoposide as first-line therapy for extensive disease small cell lung cancer: a phase II trial of a platinum-free regimen. Lung cancer (Amsterdam, Netherlands), 2005, Volume: 48, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Etoposide; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Survival Analysis; Thrombocytopenia; Topotecan; Treatment Outcome	2005
Topotecan plus ifosfamide in patients with platinum refractory advanced/metastatic non-small cell lung cancer: a phase II trial. Oncology reports, 2005, Volume: 14, Issue:6 Topics: Adult; Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Female; Humans; Ifosfamide; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neutropenia; Platinum; Thrombocytopenia; Topotecan; Treatment Outcome	2005
Topotecan by 21-day continuous infusion in children with relapsed or refractory solid tumors: a Children's Oncology Group study. Pediatric blood & cancer, 2006, Volume: 47, Issue:6 Topics: Adolescent; Adult; Astrocytoma; Child; Child, Preschool; Dose-Response Relationship, Drug; Fatigue; Female; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Neoplasm Recurrence, Local; Neuroblastoma; Neuroectodermal Tumors, Primitive; Neutropenia; Recurrence; Sarcoma; Survival Rate; Thrombocytopenia; Time Factors; Topotecan; Treatment Outcome	2006
Phase I study of docetaxel and topotecan in patients with advanced malignancies. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2005, Volume: 11, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bone Marrow Cells; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Injections, Intravenous; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Neutropenia; Taxoids; Thrombocytopenia; Topotecan; Treatment Outcome	2005
Phase I dose escalation study of pegylated liposomal doxorubicin (Caelyx) in combination with topotecan in patients with advanced malignancies. Investigational new drugs, 2006, Volume: 24, Issue:5 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neutropenia; Thrombocytopenia; Topotecan	2006
Weekly administration of topotecan-paclitaxel as second-line treatment in ovarian cancer. Cancer chemotherapy and pharmacology, 2007, Volume: 60, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neutropenia; Ovarian Neoplasms; Paclitaxel; Patient Compliance; Remission Induction; Thrombocytopenia; Topotecan; Treatment Outcome	2007
A multi-center phase II study of weekly topotecan as second-line therapy for small cell lung cancer. Lung cancer (Amsterdam, Netherlands), 2007, Volume: 57, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Alopecia; Anemia; Antineoplastic Agents; Carcinoma, Small Cell; Cisplatin; Cohort Studies; Combined Modality Therapy; Drug Administration Schedule; Fatigue; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Recurrence, Local; Survival Analysis; Thrombocytopenia; Time Factors; Topotecan; Vomiting	2007
Antiangiogenic activity of thalidomide in combination with fludarabine, carboplatin, and topotecan for high-risk acute myelogenous leukemia. Leukemia & lymphoma, 2007, Volume: 48, Issue:10 Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neovascularization, Pathologic; Thalidomide; Thrombocytopenia; Topotecan; Vascular Endothelial Growth Factor A; Vidarabine	2007
Phase I study of paclitaxel and topotecan in patients with advanced tumors: a cancer and leukemia group B study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:9 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Male; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Recombinant Proteins; Remission Induction; Thrombocytopenia; Topotecan; United States	1995
Phase I clinical and pharmacokinetic study of topotecan administered by a 24-hour continuous infusion. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:7 Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Female; Humans; Leukopenia; Male; Middle Aged; Neoplasms; Neutropenia; Thrombocytopenia; Topotecan	1995
Phase II study of topotecan in patients with advanced non-small-cell lung cancer previously untreated with chemotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1996, Volume: 14, Issue:2 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Camptothecin; Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Survival Rate; Thrombocytopenia; Topotecan; Treatment Outcome	1996
Pharmacokinetics and pharmacodynamics of topotecan given on a daily-times-five schedule in phase II clinical trials using a limited-sampling procedure. Cancer chemotherapy and pharmacology, 1996, Volume: 38, Issue:3 Topics: Aged; Agranulocytosis; Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Feasibility Studies; Female; Humans; Infusion Pumps; Infusions, Intravenous; Male; Middle Aged; Ovarian Neoplasms; Thrombocytopenia; Topoisomerase I Inhibitors; Topotecan	1996
Phase I trial and pharmacologic trial of sequences of paclitaxel and topotecan in previously treated ovarian epithelial malignancies: a Gynecologic Oncology Group study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1997, Volume: 15, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Schedule; Feasibility Studies; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Nausea; Neutropenia; Ovarian Neoplasms; Paclitaxel; Thrombocytopenia; Topotecan; Vomiting	1997
Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1997, Volume: 15, Issue:3 Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Camptothecin; Diarrhea; Drug Administration Schedule; Female; Half-Life; Humans; Leukopenia; Male; Middle Aged; Neoplasms; Thrombocytopenia; Topotecan	1997
Phase II trial to topotecan in hepatocellular carcinoma: a Southwest Oncology Group study. Investigational new drugs, 1997, Volume: 15, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Carcinoma, Hepatocellular; Enzyme Inhibitors; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neutropenia; Thrombocytopenia; Topoisomerase I Inhibitors; Topotecan	1997
Phase I study of daily times five topotecan and single injection of cisplatin in patients with previously untreated non-small-cell lung carcinoma. Annals of oncology : official journal of the European Society for Medical Oncology, 1997, Volume: 8, Issue:10 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Injections, Intravenous; Lung Neoplasms; Male; Middle Aged; Neutropenia; Thrombocytopenia; Topotecan	1997
Continuous infusion of low-dose topotecan: pharmacokinetics and pharmacodynamics during a phase II study in patients with small cell lung cancer. Anti-cancer drugs, 1998, Volume: 9, Issue:5 Topics: Adult; Aged; Anemia; Antineoplastic Agents; Biomarkers; Carcinoma, Small Cell; Data Interpretation, Statistical; Dose-Response Relationship, Drug; Female; Humans; Infusions, Intravenous; Leukopenia; Lung Neoplasms; Male; Middle Aged; Nausea; Thrombocytopenia; Topotecan; Treatment Outcome; Vomiting	1998
Phase I and pharmacologic study of continuous infusion topotecan in combination with cisplatin in patients with advanced cancer: a Cancer and LeukemiaGroup B study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998, Volume: 16, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose-Response Relationship, Drug; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Neutropenia; Thrombocytopenia; Topotecan	1998
Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998, Volume: 16, Issue:10 Topics: Adult; Aged; Antineoplastic Agents; Carboplatin; Carcinoma; Cisplatin; Drug Administration Schedule; Female; Humans; Leukopenia; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Ovarian Neoplasms; Paclitaxel; Thrombocytopenia; Topotecan; Treatment Outcome	1998
Effect of prolonged topotecan infusion on topoisomerase 1 levels: a phase I and pharmacodynamic study. Clinical cancer research : an official journal of the American Association for Cancer Research, 1997, Volume: 3, Issue:8 Topics: Adult; Aged; Antineoplastic Agents; DNA Topoisomerases, Type I; Female; Humans; Infusions, Intravenous; Leukocytes, Mononuclear; Leukopenia; Male; Middle Aged; Neoplasms; Thrombocytopenia; Topotecan	1997
Phase I clinical and plasma and cellular pharmacological study of topotecan without and with granulocyte colony-stimulating factor. Clinical cancer research : an official journal of the American Association for Cancer Research, 1996, Volume: 2, Issue:9 Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Diarrhea; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA, Neoplasm; Drug Therapy, Combination; Female; Granulocyte Colony-Stimulating Factor; Headache; Humans; Infusions, Intravenous; Leukocytes, Mononuclear; Male; Middle Aged; Nausea; Neoplasms; Neutropenia; Skin Diseases; Thrombocytopenia; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan; Treatment Outcome; Vomiting	1996
Phase I and pharmacologic study of the combination of paclitaxel, cisplatin, and topotecan administered intravenously every 21 days as first-line therapy in patients with advanced ovarian cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Cisplatin; Fatigue; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Middle Aged; Nausea; Neoplasm Staging; Neutropenia; Ovarian Neoplasms; Paclitaxel; Thrombocytopenia; Topotecan	1999
Phase I trial of paclitaxel, carboplatin, and topotecan with or without filgrastim (granulocyte-colony stimulating factor) in the treatment of patients with advanced, refractory cancer. Cancer, 1999, Mar-01, Volume: 85, Issue:5 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carboplatin; Feasibility Studies; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Recombinant Proteins; Thrombocytopenia; Topotecan; Treatment Outcome	1999
Decreased topotecan platelet toxicity with successive topotecan treatment cycles in advanced ovarian cancer patients. Anti-cancer drugs, 1999, Volume: 10, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Platelet Count; Prospective Studies; Thrombocytopenia; Topotecan	1999
Results of topotecan-based combination therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia. Seminars in hematology, 1999, Volume: 36, Issue:4 Suppl 8 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Karyotyping; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Neutropenia; Platelet Count; Remission Induction; Risk Assessment; Survival Rate; Thrombocytopenia; Topotecan	1999
A randomized phase II trial of two schedules of topotecan for the treatment of advanced stage non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands), 2000, Volume: 28, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Thrombocytopenia; Topotecan; Treatment Outcome	2000
The addition of topotecan to carboplatin and paclitaxel as first-line therapy for advanced ovarian cancer; is it possible only with peripheral blood stem cell support? European journal of gynaecological oncology, 2000, Volume: 21, Issue:1 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dose-Response Relationship, Drug; Female; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Thrombocytopenia; Topotecan	2000
Phase II evaluation of 24-h continuous infusion topotecan in recurrent, potentially platinum-sensitive ovarian cancer: A Gynecologic Oncology Group study. Gynecologic oncology, 2000, Volume: 77, Issue:1 Topics: Adult; Aged; Antineoplastic Agents; Drug Evaluation; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Ovarian Neoplasms; Palliative Care; Thrombocytopenia; Topotecan; Treatment Outcome	2000
Phase II study of oral topotecan in advanced non-small cell lung cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2000, Volume: 6, Issue:3 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Anemia; Antineoplastic Agents; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Staging; Neutropenia; Thrombocytopenia; Topotecan; Treatment Outcome; Vomiting	2000
Phase I pharmacologic study of oral topotecan and intravenous cisplatin: sequence-dependent hematologic side effects. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Cisplatin; Cross-Over Studies; Drug Administration Schedule; Drug Interactions; Feasibility Studies; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Neutropenia; Thrombocytopenia; Topotecan	2000
A phase I study of liposomal doxorubicin (Doxil) with topotecan. American journal of clinical oncology, 2000, Volume: 23, Issue:3 Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Ovarian Neoplasms; Thrombocytopenia; Topotecan	2000
Phase II trial of topotecan in patients with advanced, persistent, or recurrent uterine leiomyosarcomas: a Gynecologic Oncology Group Study. American journal of clinical oncology, 2000, Volume: 23, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Cohort Studies; Disease Progression; Drug Administration Schedule; Female; Humans; Injections, Intravenous; Leiomyosarcoma; Leukopenia; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neutropenia; Remission Induction; Thrombocytopenia; Topotecan; Uterine Neoplasms	2000
A dose escalating study of topotecan preceding cisplatin in previously untreated patients with small-cell lung cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2000, Volume: 11, Issue:7 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neutropenia; Thrombocytopenia; Topotecan	2000
A prospective randomized phase II trial of GM-CSF priming to prevent topotecan-induced neutropenia in chemotherapy-naive patients with malignant melanoma or renal cell carcinoma. Blood, 2001, Apr-01, Volume: 97, Issue:7 Topics: Anemia; Antineoplastic Agents; Carcinoma, Renal Cell; Diabetes Mellitus, Type 1; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Hypotension; Kidney Neoplasms; Melanoma; Neutropenia; Premedication; Prospective Studies; Remission Induction; Severity of Illness Index; Skin Neoplasms; Stroke; Thrombocytopenia; Topotecan; Treatment Outcome	2001
A weekly regimen of cisplatin, paclitaxel and topotecan with granulocyte-colony stimulating factor support for patients with extensive disease small cell lung cancer: a phase II study. British journal of cancer, 2001, May-04, Volume: 84, Issue:9 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Taxoids; Thrombocytopenia; Topotecan	2001
A phase I-II trial of topotecan and gemcitabine in patients with previously treated, advanced non-small cell lung cancer (LOA-3). Cancer investigation, 2001, Volume: 19, Issue:5 Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neutropenia; Thrombocytopenia; Topotecan; Treatment Outcome	2001
A phase I trial of topotecan and gemcitabine administered weekly for 3 consecutive weeks to patients with advanced tumors. Cancer, 2001, Jul-15, Volume: 92, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Thrombocytopenia; Topotecan; Treatment Outcome	2001
A phase I clinical trial of topotecan given every 2 weeks in patients with refractory solid tumors. Oncology, 2001, Volume: 61, Issue:4 Topics: Adult; Aged; Anemia; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Melanoma; Middle Aged; Neoplasms; Neutropenia; Ovarian Neoplasms; Thrombocytopenia; Topotecan; Uterine Cervical Neoplasms	2001

Other Studies

6 other study(ies) available for topotecan and Thrombocytopenia

Article	Year
[Effectiveness of CLAT Protocol for Treating Patients with Refractory Acute Myeloid Leukemia]. Zhongguo shi yan xue ye xue za zhi, 2016, Volume: 24, Issue:2 Topics: Adolescent; Adult; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Thrombocytopenia; Topotecan; Young Adult	2016
A new therapeutical approach: topotecan plus gemcitabine in the treatment of patients with relapsed ovarian cancer after failure of first-line chemotherapy with paclitaxel and platinum. The journal of obstetrics and gynaecology research, 2003, Volume: 29, Issue:3 Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Deoxycytidine; Female; Gemcitabine; Humans; Leukopenia; Neoplasm Recurrence, Local; Neutropenia; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Survival Rate; Thrombocytopenia; Topotecan; Treatment Failure	2003
Addition of topotecan to standard cisplatin/etoposide combination in patients with extended stage small cell lung carcinoma. Lung cancer (Amsterdam, Netherlands), 2007, Volume: 57, Issue:1 Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Drug Administration Schedule; Etoposide; Feasibility Studies; Female; Follow-Up Studies; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Survival Analysis; Thrombocytopenia; Time Factors; Topotecan	2007
Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1996, Volume: 14, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Agranulocytosis; Antineoplastic Agents; Camptothecin; Carcinoma, Small Cell; Cisplatin; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Thrombocytopenia; Topotecan	1996
Profound thrombocytopenia in previously treated patients with recurrent ovarian carcinoma receiving topotecan. Gynecologic oncology, 1998, Volume: 69, Issue:2 Topics: Antineoplastic Agents; Carcinoma; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platelet Count; Thrombocytopenia; Topotecan	1998
Profound thrombocytopenia in previously treated patients with recurrent ovarian carcinoma receiving topotecan. Gynecologic oncology, 1998, Volume: 69, Issue:2 Topics: Antineoplastic Agents; Autoantibodies; Carcinoma; Female; Humans; Immunoelectrophoresis; Neoplasm Recurrence, Local; Neurons; Ovarian Neoplasms; Thrombocytopenia; Topotecan	1998